



UNIVERSITY OF LEEDS

This is a repository copy of *The dynamics of response as measured by multiple composite outcome tools in the Tight Control of inflammation in early Psoriatic Arthritis (TICOPA) trial*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/116102/>

Version: Supplemental Material

Article:

Coates, LC, Mahmood, F, Emery, P et al. (2 more authors) (2017) The dynamics of response as measured by multiple composite outcome tools in the Tight Control of inflammation in early Psoriatic Arthritis (TICOPA) trial. *Annals of the Rheumatic Diseases*, 76 (10). ISSN 0003-4967

<https://doi.org/10.1136/annrheumdis-2017-211137>

© The Authors 2017. Published by BMJ Publishing Group Ltd (& EULAR). This is an author produced version of a paper published in *Annals of the Rheumatic Diseases*. Uploaded in accordance with the publisher's self-archiving policy. No commercial use is permitted unless otherwise expressly granted.

Reuse

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Supplementary table S3. Numbers (%) of patients in each CPDAI domain at (a) baseline and (b) 48 weeks.

(a) baseline

		None (0)	Mild (1)	Moderate (2)	Severe (3)	Total
Peripheral Arthritis	Tight control	0	23(23)	19 (19)	59 (58)	101 (100)
	Standard Care	0	33 (32)	18 (18)	51 (50)	102 (100)
Skin Disease	Tight control	20 (21)	72 (74)	2 (2)	3 (3)	97 (100)
	Standard care	12 (12)	84 (85)	0 (0)	3 (3)	99 (100)
Enthesitis	Tight control	19 (19)	21 (21)	49 (48)	12 (12)	101 (100)
	Standard care	25 (25)	25 (25)	43 (42)	8 (8)	102 (100)
Dactylitis	Tight control	66 (65)	7 (7)	23 (22)	6 (6)	102 (100)
	Standard care	78 (75)	11 (11)	11 (11)	4 (3)	104 (100)
Spinal Disease	Tight control	0 (0)	20 (22)	21 (24)	49 (54)	90 (100)
	Standard care	0 (0)	23 (26)	28 (32)	38 (42)	89 (100)

(b) 48 weeks

		None (0)	Mild (1)	Moderate (2)	Severe (3)	Total
Peripheral Arthritis	Tight control	24 (24)	42 (42)	11 (11)	24 (23)	101 (100)
	Standard Care	15 (14)	46 (44)	10 (10)	34 (32)	105 (100)
Skin Disease	Tight control	47 (47)	53 (52)	1 (1)	0 (0)	101 (100)
	Standard care	32 (31)	69 (66)	1 (1)	0 (0)	105 (100)
Enthesitis	Tight control	52 (51)	23 (23)	18 (18)	8 (8)	101 (100)
	Standard care	40 (38)	27 (26)	30 (29)	8 (7)	105 (100)
Dactylitis	Tight control	93 (92)	4 (4)	3 (3)	1 (1)	101 (100)
	Standard care	90 (86)	7 (7)	6 (5)	2 (2)	105 (100)
Spinal Disease	Tight control	0 (0)	66 (66)	10 (10)	24 (24)	100 (100)
	Standard care	0 (0)	59 (56)	13 (13)	33 (31)	105 (100)